



UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

On January 31, 2022 the Commission granted approval to Sartorius Stedim Biotech S.A. to purchase Novasep Process SAS. The companies compete and innovate together to develop and market chromatography technologies, which assist in the production of pharmaceuticals. Sartorius was subject to a prior approval for any future acquisition of Novasep as part of the Commission's March 2020 Danaher/GE Health consent, where Sartorius was the Commission-approved divestiture buyer.¹ This grant is the first prior approval grant in recent years affirmatively approving a merger,² and follows the Commission's adoption of a policy concerning prior approval in October.
